4-aminopyridine has been researched along with Cerebellar Ataxia in 10 studies
Cerebellar Ataxia: Incoordination of voluntary movements that occur as a manifestation of CEREBELLAR DISEASES. Characteristic features include a tendency for limb movements to overshoot or undershoot a target (dysmetria), a tremor that occurs during attempted movements (intention TREMOR), impaired force and rhythm of diadochokinesis (rapidly alternating movements), and GAIT ATAXIA. (From Adams et al., Principles of Neurology, 6th ed, p90)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia." | 5.72 | The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022) |
| "Pharmacological treatment of cerebellar ataxias and cerebellar nystagmus still remains difficult." | 2.53 | Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus. ( Bremova, T; Feil, K; Muth, C; Schniepp, R; Strupp, M; Teufel, J, 2016) |
| "Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia." | 1.72 | The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Mingot, C | 1 |
| López-Ortega, R | 1 |
| Brieva-Ruiz, L | 1 |
| Giordano, I | 1 |
| Bogdanow, M | 1 |
| Jacobi, H | 1 |
| Jahn, K | 2 |
| Minnerop, M | 1 |
| Schoels, L | 1 |
| Synofzik, M | 1 |
| Teufel, J | 2 |
| Klockgether, T | 1 |
| Abbasi, S | 2 |
| Abbasi, A | 2 |
| Sarbaz, Y | 2 |
| Feil, K | 1 |
| Bremova, T | 1 |
| Muth, C | 1 |
| Schniepp, R | 2 |
| Strupp, M | 4 |
| Alviña, K | 1 |
| Khodakhah, K | 1 |
| Wuehr, M | 1 |
| Ackl, N | 1 |
| Danek, A | 1 |
| Brandt, T | 3 |
| Kalla, R | 1 |
| Freilinger, T | 1 |
| Dichgans, M | 1 |
| Sprenger, A | 1 |
| Rambold, H | 1 |
| Sander, T | 1 |
| Marti, S | 1 |
| Weber, K | 1 |
| Straumann, D | 1 |
| Helmchen, C | 1 |
| Zwergal, A | 1 |
2 reviews available for 4-aminopyridine and Cerebellar Ataxia
| Article | Year |
|---|---|
Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.
Topics: 4-Aminopyridine; Cerebellar Ataxia; Chlorzoxazone; Drug Therapy; Humans; Leucine; Muscle Relaxants, | 2016 |
Episodic ataxia type 2.
Topics: 4-Aminopyridine; Acetazolamide; Animals; Calcium Channels; Carbonic Anhydrase Inhibitors; Cerebellar | 2007 |
1 trial available for 4-aminopyridine and Cerebellar Ataxia
| Article | Year |
|---|---|
Treatment of the gravity dependence of downbeat nystagmus with 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Cerebellar Ataxia; Electrooculograph | 2006 |
7 other studies available for 4-aminopyridine and Cerebellar Ataxia
| Article | Year |
|---|---|
The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2.
Topics: 4-Aminopyridine; Acetazolamide; Adult; Ataxia; Cerebellar Ataxia; Female; Humans; Male; Middle Aged; | 2022 |
Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia.
Topics: 4-Aminopyridine; Cerebellar Ataxia; Chronic Disease; Disability Evaluation; Humans; Potassium Channe | 2013 |
Combination of BK channel opener and Kv4 channel inhibitor for treatment of cerebellar ataxia in mutant med mice.
Topics: 4-Aminopyridine; Acetazolamide; Animals; Cerebellar Ataxia; Large-Conductance Calcium-Activated Pota | 2013 |
Introducing treatment strategy for cerebellar ataxia in mutant med mice: combination of acetazolamide and 4-aminopyridine.
Topics: 4-Aminopyridine; Acetazolamide; Action Potentials; Animals; Cerebellar Ataxia; Disease Models, Anima | 2014 |
The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Behavior, Animal; Cerebellar Ataxia; | 2010 |
4-Aminopyridine improves gait variability in cerebellar ataxia due to CACNA 1A mutation.
Topics: 4-Aminopyridine; Aged; Calcium Channels; Cerebellar Ataxia; Gait Disorders, Neurologic; Humans; Male | 2011 |
Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia--a comment.
Topics: 4-Aminopyridine; Adult; Calcium Channels, N-Type; Cerebellar Ataxia; Epilepsy, Absence; Female; Huma | 2005 |